Author

U. Matulonis

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

A. D. D'Andrea· 1 shared A. Font-Tello· 1 shared A. G. Waks· 1 shared A. Gusev· 1 shared B. J. Abraham· 1 shared B. Kochupurakkal· 1 shared B. Y. Karlan· 1 shared C. E. Dunn· 1 shared

Activity by Year

2019-2019 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. D. D'Andrea

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Predicting master transcription factors from pan-cancer expression data

J. Reddy, M. A. S. Fonseca, R. I. Corona, R. Nameki, F. Segato Dezem, I. A. Klein, H. Chang, D. Chaves-Moreira, L. Afeyan, T. M. Malta, X. Lin, F. Abbasi, A. Font-Tello, T. Sabedot, P. Cejas, , K. Lawrenson

This paper introduces CaCTS, an algorithm that identifies candidate master transcription factors (MTFs) across 34 cancer types using RNA-seq data, revealing novel MTFs and functional groupings.

bioRxiv · Nov 12, 2019Cancer Biology

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer

A. G. Waks, O. Cohen, B. Kochupurakkal, D. Kim, C. E. Dunn, J. Buendia Buendia, S. Wander, K. Helvie, M. R. Lloyd, L. Marini, M. E. Hughes, S. S. Freeman, S. P. Ivy, J. Geradts, S. Isakoff, , N. Wagle

This study identifies genomic reversion and increased DNA end resection as mechanisms of resistance to PARP inhibitors and platinum in BRCA1/2-mutant metastatic breast cancer, with RAD51 foci as a potential biomarker.

bioRxiv · Nov 10, 2019Cancer Biology